MIRAMAR, Fla., Oct. 25, 2019 (GLOBE NEWSWIRE) -- /
Post# of 36568
(Total Views: 333)
Posted On: 10/25/2019 11:25:18 AM
MIRAMAR, Fla., Oct. 25, 2019 (GLOBE NEWSWIRE) -- /(Business Wire)/-- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the results of the annual meeting of the Company’s stockholders held on October 25, 2019. Brian McGee, Dr. James H. Anderson, Jr., MD, Dr. Craig Eagle, MD, and Larry Salvo were re-elected as independent members of the Company’s Board of Directors. Omar Gzouli and Mark Prioletti were elected as new independent Board Members, and Joseph Moscato, the Company’s President & Chief Executive Officer, and Andrew Ro, the Company’s Chief Investment Officer, were also re-elected to the Board.
The proposal to ratify the appointment of Mazurs USA LLP as independent public accountants in respect of the Company’s fiscal year-end was approved by the stockholders.
A Form 8-K Current Report in respect of the specific voting results will be filed with the U.S. Securities and Exchange Commission today.
The Company intends to schedule an investor conference call in the coming weeks to update stockholders on the effectuation of the Company’s business plans.
Mr. Moscato commented: “I am pleased that the holders of over 70% of the Company’s outstanding shares cast votes at the meeting and that my fellow stockholders have supported Generex management with the approval of our Board of Directors and a vote of confidence in our go-forward plans. Welcome to our new board members Omar Gzouli and Mark Prioletti; it is a pleasure to work with you and the rest of our board to make Generex a success.”
Mr. Moscato further stated: “In the last year, we have made significant progress on the Generex strategic plan, building value for our shareholders, as detailed in our 10K annual report that will be filed in the coming days. I would like to congratulate the Generex Board and management team on the successful implementation of our three-phase plan that to bring GNBT back to the Nasdaq national market. In the coming weeks, we will host an investor conference call to highlight company achievements as we continue to pursue our Nasdaq up-listing and the NuGenerex Immuno-Oncology merger and separate listing on the public markets. During the call we will also introduce our newest acquisition, ALTuCELL, and discuss our new business venture to implement our end-to-end strategy for diabetes care, from discovery to bedside, with Arizona Endocrinology Center and Paradise Valley Family Medicine. We look forward to an exciting and rewarding 2020.”
The proposal to ratify the appointment of Mazurs USA LLP as independent public accountants in respect of the Company’s fiscal year-end was approved by the stockholders.
A Form 8-K Current Report in respect of the specific voting results will be filed with the U.S. Securities and Exchange Commission today.
The Company intends to schedule an investor conference call in the coming weeks to update stockholders on the effectuation of the Company’s business plans.
Mr. Moscato commented: “I am pleased that the holders of over 70% of the Company’s outstanding shares cast votes at the meeting and that my fellow stockholders have supported Generex management with the approval of our Board of Directors and a vote of confidence in our go-forward plans. Welcome to our new board members Omar Gzouli and Mark Prioletti; it is a pleasure to work with you and the rest of our board to make Generex a success.”
Mr. Moscato further stated: “In the last year, we have made significant progress on the Generex strategic plan, building value for our shareholders, as detailed in our 10K annual report that will be filed in the coming days. I would like to congratulate the Generex Board and management team on the successful implementation of our three-phase plan that to bring GNBT back to the Nasdaq national market. In the coming weeks, we will host an investor conference call to highlight company achievements as we continue to pursue our Nasdaq up-listing and the NuGenerex Immuno-Oncology merger and separate listing on the public markets. During the call we will also introduce our newest acquisition, ALTuCELL, and discuss our new business venture to implement our end-to-end strategy for diabetes care, from discovery to bedside, with Arizona Endocrinology Center and Paradise Valley Family Medicine. We look forward to an exciting and rewarding 2020.”
(1)
(0)